STRATA Skin Sciences (SSKN) announces its participation in the 2025 Ibero-Latin American Congress of Dermatology November 19-22, 2025, where it presented its XTRAC excimer laser and TheraclearX acne therapy system. STRATA also reported that, by the end of 2025, there will be over 12 new recurring TheraclearX accounts in Mexico. CEO Dolev Rafaeli added, “While it is still early to estimate what will be the commercial value of each of these individual placements, time has shown with our XTRAC placements in other countries that when the partner clinic is fully developed, STRATA can realize upwards of $30,000 in annual revenue per clinic.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SSKN:
- Strata Skin Sciences Earnings Call: Mixed Sentiment Amid Market Expansion
- STRATA Skin Sciences Reports Q3 2025 Financial Results
- Strata Skin Sciences Reports Q3 2025 Revenue Decline
- SSKN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Strata Skin Sciences announces CMS recognition of expanded CPT codes